1
|
Gagliardi S, Truffi M, Tinelli V, Garofalo M, Pandini C, Cotta Ramusino M, Perini G, Costa A, Negri S, Mazzucchelli S, Bonizzi A, Sitia L, Busacca M, Sevieri M, Mocchi M, Ricciardi A, Prosperi D, Corsi F, Cereda C, Morasso C. Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer's Disease Patients. Int J Mol Sci 2022; 23:9237. [PMID: 36012501 PMCID: PMC9409287 DOI: 10.3390/ijms23169237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Revised: 08/01/2022] [Accepted: 08/06/2022] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Bisdemethoxycurcumin (BDC) might be an inflammation inhibitor in Alzheimer's Disease (AD). However, BDC is almost insoluble in water, poorly absorbed by the organism, and degrades rapidly. We thus developed a new nanoformulation of BDC based on H-Ferritin nanocages (BDC-HFn). METHODS We tested the BDC-HFn solubility, stability, and ability to cross a blood-brain barrier (BBB) model. We tested the effect of BDC-HFn on AD and control (CTR) PBMCs to evaluate the transcriptomic profile by RNA-seq. RESULTS We developed a nanoformulation with a diameter of 12 nm to improve the solubility and stability. The comparison of the transcriptomics analyses between AD patients before and after BDC-HFn treatment showed a major number of DEG (2517). The pathway analysis showed that chemokines and macrophages activation differed between AD patients and controls after BDC-HFn treatment. BDC-HFn binds endothelial cells from the cerebral cortex and crosses through a BBB in vitro model. CONCLUSIONS Our data showed how BDC-Hfn could improve the stability of BDC. Significant differences in genes associated with inflammation between the same patients before and after BDC-Hfn treatment have been found. Inflammatory genes that are upregulated between AD and CTR after BDC-HFn treatment are converted and downregulated, suggesting a possible therapeutic approach.
Collapse
Affiliation(s)
| | - Marta Truffi
- Istituti Clinici Scientifici Maugeri IRCCS Spa SB, 27100 Pavia, Italy
| | - Veronica Tinelli
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milano, Italy
| | | | | | | | | | - Alfredo Costa
- IRCCS Mondino Foundation, 27100 Pavia, Italy
- Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy
| | - Sara Negri
- Istituti Clinici Scientifici Maugeri IRCCS Spa SB, 27100 Pavia, Italy
| | - Serena Mazzucchelli
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via G. B. Grassi 74, 20157 Milano, Italy
| | - Arianna Bonizzi
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via G. B. Grassi 74, 20157 Milano, Italy
| | - Leopoldo Sitia
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via G. B. Grassi 74, 20157 Milano, Italy
| | | | - Marta Sevieri
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via G. B. Grassi 74, 20157 Milano, Italy
| | - Michela Mocchi
- Istituti Clinici Scientifici Maugeri IRCCS Spa SB, 27100 Pavia, Italy
| | | | - Davide Prosperi
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milano, Italy
| | - Fabio Corsi
- Istituti Clinici Scientifici Maugeri IRCCS Spa SB, 27100 Pavia, Italy
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milano, Italy
- Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via G. B. Grassi 74, 20157 Milano, Italy
| | | | - Carlo Morasso
- Istituti Clinici Scientifici Maugeri IRCCS Spa SB, 27100 Pavia, Italy
| |
Collapse
|
2
|
Everest-Dass AV, Moh ESX, Ashwood C, Shathili AMM, Packer NH. Human disease glycomics: technology advances enabling protein glycosylation analysis - part 2. Expert Rev Proteomics 2018. [PMID: 29521143 DOI: 10.1080/14789450.2018.1448710] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
INTRODUCTION The changes in glycan structures have been attributed to disease states for several decades. The surface glycosylation pattern is a signature of physiological state of a cell. In this review we provide a link between observed substructural glycan changes and a range of diseases. Areas covered: We highlight biologically relevant glycan substructure expression in cancer, inflammation, neuronal diseases and diabetes. Furthermore, the alterations in antibody glycosylation in a disease context are described. Expert commentary: Advances in technologies, as described in Part 1 of this review have now enabled the characterization of specific glycan structural markers of a range of disease states. The requirement of including glycomics in cross-disciplinary omics studies, such as genomics, proteomics, epigenomics, transcriptomics and metabolomics towards a systems glycobiology approach to understanding disease mechanisms and management are highlighted.
Collapse
Affiliation(s)
- Arun V Everest-Dass
- a Faculty of Science and Engineering, Biomolecular Discovery and Design Research Centre , Macquarie University , Sydney , Australia.,b ARC Centre for Nanoscale BioPhotonics , Macquarie University , Sydney , Australia.,c Institute for Glycomics , Griffith University , Gold Coast , Australia
| | - Edward S X Moh
- a Faculty of Science and Engineering, Biomolecular Discovery and Design Research Centre , Macquarie University , Sydney , Australia.,b ARC Centre for Nanoscale BioPhotonics , Macquarie University , Sydney , Australia
| | - Christopher Ashwood
- a Faculty of Science and Engineering, Biomolecular Discovery and Design Research Centre , Macquarie University , Sydney , Australia.,b ARC Centre for Nanoscale BioPhotonics , Macquarie University , Sydney , Australia
| | - Abdulrahman M M Shathili
- a Faculty of Science and Engineering, Biomolecular Discovery and Design Research Centre , Macquarie University , Sydney , Australia.,b ARC Centre for Nanoscale BioPhotonics , Macquarie University , Sydney , Australia
| | - Nicolle H Packer
- a Faculty of Science and Engineering, Biomolecular Discovery and Design Research Centre , Macquarie University , Sydney , Australia.,b ARC Centre for Nanoscale BioPhotonics , Macquarie University , Sydney , Australia.,c Institute for Glycomics , Griffith University , Gold Coast , Australia
| |
Collapse
|
3
|
Lu'o'ng KVQ, Nguyen LTH. The role of vitamin D in Alzheimer's disease: possible genetic and cell signaling mechanisms. Am J Alzheimers Dis Other Demen 2013; 28:126-36. [PMID: 23322908 PMCID: PMC10852937 DOI: 10.1177/1533317512473196] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Alzheimer's disease (AD) is the most common form of dementia in the elderly individuals and is associated with progressive memory loss and cognitive dysfunction. A significant association between AD and low levels of vitamin D has been demonstrated. Furthermore, vitamin D supplements appear to have a beneficial clinical effect on AD by regulating micro-RNA, enhancing toll-like receptors, modulating vascular endothelial factor expression, modulating angiogenin, and advanced glycation end products. Vitamin D also exerts its effects on AD by regulating calcium-sensing receptor expression, enhancing amyloid-β peptides clearance, interleukin 10, downregulating matrix metalloproteinases, upregulating heme oxygenase 1, and suppressing the reduced form of nicotinamide adenine dinucleotide phosphate expression. In conclusion, vitamin D may play a beneficial role in AD. Calcitriol is the best vitamin D supplement for AD, because it is the active form of the vitamin D3 metabolite and modulates inflammatory cytokine expression. Therefore, further investigation of the role of calcitriol in AD is needed.
Collapse
Affiliation(s)
- Khanh Vinh Quoc Lu'o'ng
- Vietnamese American Medical Research Foundation, 14971 Brookhurst St. Westminster, CA 92683, USA.
| | | |
Collapse
|